Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Cisplatin; Belgium: Cisplatine, Platosin; Bulgaria: Cisplatin, Sinplatin; Cyprus: Cisplatin; Czech Republic: Cisplatin, Platidiam, Platosin; Denmark: Cisplatin; Estonia: Cisplatin; Finland: Cisplatin; France: Cisplatine, Cisplatyl; Germany: Cis-GRY, Cisplatin, Platinol, Ribocis; Greece: Cisplatin, Cisplatyl, Oncoplat, Platamine; Hungary: Cisplatin, Platidiam; Ireland: Cisplatin; Italy: Cisplatin, Platamine; Latvia: Cisplatin, Cytoplatin; Lithuania: Cisplatin; Luxembourg: Cisplatine, Cisplatinum, Platistine; Malta: Cisplatin; Netherlands: Cisplatine, Platosin; Poland: Blastolem, Cisplatin, Platamine, Platidiam; Portugal: Cisplatina; Romania: Cisplatin, Sinplatin; Slovakia: Cisplatin, Platidiam, Platis; Slovenia: Cisplatin, Platinex; Spain: Cisplatino; Sweden: Cisplatin; UK: Cisplatin.

North America

Canada: Cisplatin; USA: Cisplatin, Platinol.

Latin America

Argentina: Cisplatino, Elvecis, Platino II, Sicatem; Brazil: Cisplatex, Citoplax, C-Platin-Cisplatina, Incel, Platiran, Platistine CS, Tecnoplatin; Mexico: Blastolem RU, Noveldexis, Platinol.


Japan: Briplatin, Cisplamerck, Cisplatin, IA-call, Platosin, Randa.

Drug combinations

Cisplatin and Docetaxel

Cisplatin, Carmustine, and Dacarbazine

Cisplatin, Dacarbazine, and Vinblastine

Cisplatin, Docetaxel, and Fluorouracil

Cisplatin, Docetaxel, and Trastuzumab

Cisplatin, Aldesleukin, Dacarbazine, and Interferon Alpha-2b

Cisplatin, Carmustine, Dacarbazine, and Tamoxifen


Cisplatin: Cl~2~H~6~N~2~Pt. Mw: 300.05. (1) Platinum, diamminedichloro-, (SP-4-2)-; (2) cis-Diamminedichloroplatinum. CAS-15663-27-1 (1977).

Pharmacologic Category

Other Antineoplastic Agents; Platinum Compounds. (ATC-Code: L01XA01).

Mechanism of action

Forms platinum complexes that bind to specific DNA base sequences, producing intrastrand and interstrand DNA cross-links, which are thought to inhibit DNA replication, transcription, and ultimately cell division. Denatures the double helix. Covalently binds to DNA bases and disrupts DNA function. May also bind to proteins. Cisplatin can also bind two adjacent guanines on the same strand of DNA producing intrastrand cross-linking and breakage. Cycle-phase nonspecific. Exhibits immunosuppressive, radiosensitizing, and antimicrobial properties. Possible cross-resistance with carboplatin.

Therapeutic use

Bladder cancer. Testicular cancer. Ovarian cancer.

Pregnancy and lactiation implications

Teratogenicity and embryotoxicity in animal studies. There are no adequate studies in pregnant women. May be toxic to fetal urogenital tract. Enters breast milk.

Unlabeled use

Head and neck, breast, gastric, lung, esophageal, cervical, prostate and small cell lung cancer. Hodgkin’s and non-Hodgkin lymphoma. Neuroblastoma. Sarcomas, myeloma, melanoma, mesothelioma, and osteosarcoma.


Hypersensitivity to cisplatin, other platinum-containing compounds, or any component of the formulation (anaphylactic-like reactions reported). Pre-existing renal insufficiency. Myelosuppression. Hearing impairment. Pregnancy.

Warnings and precautions

Anaphylactic-like reactions reported. Myelosuppression, nausea, and vomiting are dose-related toxicities. Severe and possibly irreversible neuropathies may occur with higher than recommended doses or more frequent regimen. Ototoxicity, especially pronounced in children. Cumulative renal toxicity may be severe. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives (carboplatin, cisplatin). Caution in the elderly (may be more susceptible to nephrotoxicity and peripheral neuropathy).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart